What 9,000 Medicines in Development Really Demand

Written By Juliana Rissi

More than 9,000 medicines are currently in development worldwide, with nearly 1,500 drug candidates actively advancing through clinical trials.

This level of pipeline activity signals more than innovation. It reflects the scale of leadership, collaboration, and decision making required to move science forward responsibly and sustainably in 2026.

Behind every program are teams navigating complexity and opportunity with intention. Strong leadership remains essential to translating scientific promise into meaningful patient impact.

If you’re navigating leadership needs across the biotech pipeline, we welcome a conversation.

Source: International Federation of Pharmaceutical Manufacturers & Associations (IFPMA)

#HarmoniaBio #LifeSciencesLeadership #BiotechInnovation #LeadershipThatBuilds #ScientificProgress #BiotechPipeline

Juliana Rissi
Previous

Technical expertise matters, but connection makes the difference!
Next